In April 2016, we opened the doors of a scientific laboratory that now operates 24 hours a day. We conduct research into methods of cancer immunotherapy using cell-derived products in collaboration with our partners from Lithuania, Austria, Estonia and the Czech Republic.
Our research partners include National Cancer Institute, Joint Life Sciences Centre, State Research Institute, Centre for Innovative Medicine and International Consortium for Cell Therapy and Immunotherapy (ICCTI).
1.MITA project “In vitro study of anticancer properties of recombinant protein”
The recombinant Gc protein analogue developed in the company can be used in cancer patients as a potent activator of the immune system, i.e. drug for additional immunostimulation. According to the original hypotheses, the recombinant protein produced in-house can efficiently activate macrophages and thus promote anti-cancer immune responses.
Our partner in this project – National Cancer Institute.
2.Medicinal products for modulating the immune system in the field of advanced therapies for cancer treatment.
The aim of this project is to create anticancer therapeutic vaccines consisting of autologous dendritic cells, whereby the immune response is modulated using autologous or allogeneic exosomes. The plan is to design vaccines for treating three forms of localized cancer: glioblastoma, melanoma and lung cancer.
We began the project in collaboration with the National Cancer Institute on 1 March 2017 and completed it at the beginning of 2019.
3. Effectiveness of therapeutic anticancer vaccines in experimental models using mice.
The purpose of this experimental research is to evaluate and compare the effectiveness of anticancer, autologous and xenogeneic vaccines using in vivo models of melanoma and lung carcinoma in mice.
The research is being carried out with our partners from the National Cancer Institute, Innovita Research UAB and the R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology in Ukraine. The project started in September 2015 and completed in 2017 autumn.